Objective Patients with cancers frequently experience sleep and circadian dysfunction. To date, only a few studies have used both a questionnaire and actigraphy for concomitant evaluation of sleep and circadian function in patients with cancer. We sought to evaluate objective sleep and circadian parameters in metastatic colon cancer (MCC) patients and their associations with symptoms and quality of life (QOL). Methods Patients reported subjective sleep problems on the EORTC QLQ-C30. Sleep and circadian parameters were calculated using a wrist-actigraph that patients wore for 72 h. Results 237 Patients with MCC (mean age: 60.4 years; range: 20.7-77.6; Male/Female ratio: 1.66) participated in this cross-sectional study. Subjective sleep problems were reported by 63.4% of patients (S?). No differences in any sleep parameters (sleep efficiency, sleep latency, total sleep time, total time in bed, wake after sleep onset, activity bathyphase) were observed between S? and S-patients. However, S? patients displayed a significantly worse circadian function than S-patients (96.4 vs 98.1%; p = 0.005). The presence of poor subjective sleep and objective circadian dysfunction negatively affected symptoms and QOL domains (p = 0.038). Conclusions Subjective report of sleep problems was not associated with worse objectively measured sleep parameters in patients with MCC although it was associated with disrupted circadian rest-activity rhythm and poorer QOL. These findings coincide with prior research in cancer patients in that an inconsistent relationship exists between subjective and objective sleep measurements on some sleep domains. This study supports the value of coupled evaluation of self-reported and objective measures of sleep and circadian function in cancer patients.
performance, and appetite. Circadian function research seeks to understand contributors to the regulation and disruption of its processes including sleep, as well as the beneficial and harmful health consequences of circadian function regulation and disruption, respectively. Several studies have indicated that because circadian rhythm physiology is coordinated by a hierarchical system [3, 4] , disruption of the function of the circadian timing system (e.g., induced by shift work or jet-lag) is associated with several systemic complaints, such as asthenia, low vitality, poor performance, mood alterations, sleep disruption, and appetite loss [5] [6] [7] . Interestingly, these are also the symptoms most commonly reported by patients with cancer [8] . Moreover, these same systemic symptoms often cluster together in cancer patients, suggesting a common underlying pathogenic mechanism [9, 10] .
Circadian dysregulation and sleep disruption have a reciprocal relationship in that sleep disruption might adversely affect circadian function, and deregulation of circadian function can contribute to the development of sleep disruption [11] . Sleep disruption, insomnia, (difficulty falling and staying asleep or waking up earlier than intended), and nonrestorative sleep are highly prevalent issues among cancer patients and cancer survivors throughout the whole disease span [12] [13] [14] [15] . Moreover, poor, short sleep and daytime naps have been shown to be associated with an increased risk for the development of colorectal cancer in a recent meta-analysis involving about 1.5 million individuals worldwide [16] . Approximately half of colorectal cancer patients report sleep disruption [17] . Similar figures have been described for circadian disruption in this clinical setting [18, 19] . While the etiology of sleep and circadian disruption in cancer is not entirely understood, several precipitating factors include receipt of chemotherapy, diagnosis-induced stress, and side-effects from treatments [14] .
Actigraphy, a wrist-worn accelerometer, is a widely accepted measure of sleep as well as activity, thus providing an approximation of circadian activity patterns [20] . The rest-activity rhythm, which can be evaluated with an actigraph, is often a preferred biomarker of the circadian timing system compared to evaluation of serum or salivary cortisol because of its noninvasiveness, relative cost, continuity of monitoring throughout day and night, and practical considerations for patients with high disease burden. Analysis of actigraphy recordings provides relevant and robust parameters, such as the dichotomy index I \ O, which represents relative differences in activity between time spent in bed versus out of bed [21] . Better circadian function is represented by a higher I \ O index, which indicates that patients are spending the nighttime asleep in a restful way and spending the daytime awake in an active way [22] . In previous studies, I \ O has been shown to be one of the most clinically relevant circadian parameters in terms of prognosis and correlation with health-related quality of life and symptoms [18, [23] [24] [25] [26] .
Thus, there is substantial evidence to support the notion that sleep and circadian disruption are prevalent, bothersome, and clinically relevant in cancer patients. However, limited research exists in patients with metastatic colorectal cancer that has evaluated both sleep and circadian dysfunction concurrently, using both objective and subjective measures [15] . The aim of this study is to fill this knowledge gap by examining the relationship between subjective sleep problems and objective evidence of sleep and circadian disruption, as well as their association with factors related to health-related quality of life in patients with metastatic colorectal cancer.
Methods
The current descriptive study involved cross-sectional comparisons of two main groups (those with and without subjective sleep problems) and four subgroups (sleep problems with or without concomitant circadian disruption) of patients with metastatic colorectal cancer with available data for both wrist-actigraphy and the sleep item from a health-related quality of life questionnaire). Patients participated in two separate prospective studies: the first one included 145 patients [24] , and the second was a companion study to an international randomized phase III trial [27] that included 92 patients [23] . Both studies were approved by the appropriate ethics review boards at the participating research centers. All patients were adults ([18 years) who provided written informed consent, completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v2), and wore the wrist-actigraph for 3 full days and nights before receiving the first course of chemotherapy for histologically proven metastatic colorectal cancer. Patients with symptomatic brain metastases or uncontrolled endocrine, neurological, or psychiatric comorbidities were excluded.
Quality of life questionnaire and subjective sleep assessment
The EORTC QLQ-C30 is the most widely used multidimensional questionnaire for assessing health-related quality of life in cancer patients [28] . Each patient completed the test in her/his first language according to the procedures suggested by the EORTC [29] . The questionnaire includes a single straightforward question regarding sleep difficulty: ''(During the past week) Have you had trouble sleeping?'' [28] We considered that patients had no subjective sleep complaints if they answered ''not at all''. The other possible answers (i.e., ''a little'', ''quite a bit,'' and ''very much'') were considered a subjective report of sleep problems. This dichotomization exhibited clinical impact on patient outcomes in a prior study [17] . This item uniquely assesses sleep, and is a standalone question; hence, it is not included in the calculation of any other subscale of the questionnaire. We also calculated healthrelated quality of life domains and symptoms from the same questionnaire according to the recommended methodology, which involved the transformation of raw scores into a linear scale ranging from 0 to 100 [28] . For health-related quality of life domains, higher values reflect better functioning; conversely, for symptoms, higher values indicate more severe complaints. In the general population, median symptom scores are mostly 0 (except for fatigue, which is 22.2), median function scores are 100, and median global quality of life is 75 [30] .
Wrist actigraphy
Patients wore a Mini-Motionlogger actigraph (Ambulatory Monitoring Inc., USA) for 72 consecutive hours on their nondominant wrist. This device is a watch-sized piezoelectric linear accelerometer with a memory storage that records the number of limb accelerations that occur per minutes [15, 23, 24] . It is widely used in sleep and chronobiology research, particularly for its noninvasive presence in the subject's own environment [20] . Actigraphy time series were analyzed using dedicated software provided by the manufacturer (Action W, Version 2.7 and Action 4, Version 1.16; Ambulatory Monitoring Inc., USA). These programs provided validated parameters for objectively assessing sleep and circadian function. In particular, using the validated University of California San Diego algorithm to infer sleep and wake [31] , the analysis allowed the computation of average total time scored as sleep (TST), sleep efficiency (SE, percentage of TST within total time spent in bed), sleep latency (SL, min to the start of the first 20-min block with [19 min of sleep), and wake after sleep onset (WASO, duration of time scored as wake during the interval consumed in bed) [15, 32] . Furthermore, we calculated the dichotomy index I \ O, the most relevant circadian parameter in cancer research [18, 23, 24] , which indicates the percentage of activity counts during time in bed values of which are lower than the median activity out-of-bed with higher values suggesting more robust circadian function [19, 21] . Finally, we computed the clock time of the lowest activity (bathyphase) using a cosinor analysis and the average activity counts (accelerations per min). For these parameters, the best cutoff values to differentiate healthy subjects from cancer patients are 99% for I \ O, 7 h 20 min for TST, 92% for SE, 12 min for SL, and 25 min for WASO [22] .
Statistical analyses
Patients were initially categorized into two subgroups based on their report of having trouble sleeping or not, according to their answer to the question, ''(During the past week) Have you had trouble sleeping?'' on the EORTC QLQ-C30. The distribution of the aforementioned objective actigraphy sleep parameters, I \ O, average activity, and bathyphase were compared between the two categories of patients using the nonparametric Mann-Whitney U test. Following the initial results, patients were categorized into four subgroups according to subjective sleep problems (yes/no) and objective circadian disruption (''presence of circadian disruption'', dichotomy index C97.5% [18, 19] , ''no circadian disruption'', dichotomy index \97.5%) Additionally, the distribution of global quality of life measures was compared among the four subgroups using the nonparametric Kruskal-Wallis test. Differences deemed significant demonstrated p \ 0.05. Analyses were performed using PASW software 22 (SPSS, IBM, USA).
Results

Clinical features
The study included a total of 237 patients with metastatic colorectal cancer. The main demographic and medical characteristics of our study's subjects are summarized in Table 1 and generally reflect similar descriptors to those reported by clinical trials in patients with metastatic colorectal cancer. The concomitant chronic use of drugspotentially affecting sleep-proved infrequent (0.8-2.5%) in our study population (Table 1) . Eighty two patients (34.6%) described no trouble sleeping, whereas 155 patients (65.4%) complained of sleep problems on the EORTC QLQ-C30 questionnaire.
Actigraphy parameters and subjective sleep Table 2 presents the distribution of the four objective sleep parameters and the three activity measures in the whole study population. Subjective complaint of sleep trouble was not associated with a difference in the distribution of any actigraphy sleep parameter (Fig. 1) . Thus, TST duration was approximately the same whether or not the patient complained of sleep trouble (p = 0.57). Estimated difficulty falling asleep (SL) proved equally severe, and estimated duration of awakening episodes during the night (WASO) was not significantly longer in patients with subjective sleep complaints than in those who reported no trouble (p = 0.25 and p = 0.34, respectively). This produced a similar SE in both groups of patients (p = 0.61). Neither the timing of lower activity (p = 0.27) nor the average activity counts (p = 0.53) differed Table 1 Clinical and demographic characteristics of the study population (n = 237), and of the two subgroups according to the presence (n = 155; 65.4%) or absence (n = 82; 34.6%) of subjective sleep trouble As a result of this finding, we performed further post hoc analyses to explore the clinical implication of subjective sleep problems and actigraphy-derived circadian disruption. Thus, 40.1% of patients had both circadian (as characterized by a clinical cutoff of 97.5% for I \ O) and subjective sleep disruption; 25.3% had subjective sleep problems only; 14.8% had circadian disruption only, and 19.8% of patients had neither. There were significant differences between these groups on the health-related quality of life subscales: Post-hoc analyses indicated that those who had both subjective sleep problems and circadian disruption had the lowest (i.e., worst) overall health-related quality of life scores and the highest (i.e., most severe) systemic symptoms scores (Fig. 3) .
Health-related quality of life
Thus, global quality of life (p \ 0.001), physical (p \ 0.001), social (p = 0.023), and role functioning (p = 0.044) were significantly different in these four subgroups, with patients reporting trouble sleeping and exhibiting disrupted circadian function displaying worse (i.e., higher) scores. Similarly, fatigue (p = 0.029) and appetite loss (p = 0.038) were significantly different in the four subgroups and more severe (i.e., higher scores) in patients with both sleep complaints and circadian disruption (Fig. 3) .
Conclusions
To our knowledge, this study is the first one in patients with metastatic colorectal cancer that evaluated both subjective and objective sleep problems, as well as circadian function. Furthermore, this study involves a relatively large sample of patients with colorectal cancer. While the majority (65.4%) of patients reported having subjective sleep problems, their associated actigraphy-measured sleep parameters appeared to be within normal ranges [33] and remarkably comparable to those not reporting subjective sleep problems (Fig. 1) . However, another study conducted in women with early breast cancer reported a higher number of night awakening episodes than in the general population using wrist-actigraphy [15] . We found that the largest proportion (40%) of patients reported having both subjective sleep problems and circadian disruption, followed by 25% of the sample's endorsing subjective sleep problems but not meeting criteria for circadian disruption. An additional 15% met criteria for only circadian disruption, while another minority of patients (20%) had neither sleep nor circadian disruption problems. While this study observed no difference in actigraphy-measured sleep and activity variables between patients who reported subjective sleep complaints and those who self-rated themselves as good sleepers (Fig. 1) , we found significant differences in circadian function, as measured by dichotomy index, between these patient groups (Fig. 2) .
Several studies have found that subjective sleep complaints are generally correlated with actigraphy-measured variables in the general population [34] , yet studies in cancer patients sometimes showed no relationship or an inconsistent relationship between subjective and objective sleep measurements [15, 35] . While our findings are in line with prior research in cancer patients, Moore et al. propose that the discrepancy can be potentially explained by the ''importance of sleep perception'' in medically ill populations with comorbid sleep disturbance. Patients might overestimate or underestimate their sleep problems [35] , creating lack of agreement between self-reported sleep and actigraphy-measured sleep. In addition, while actigraphy is accurate in measuring sleep in healthy populations, de Souza et al. found that, even in healthy participants, actigraphy overestimates sleep latency (SL), total sleep time (TST), and sleep efficiency (SE), while it underestimates awakenings compared to the gold standard of polysomnography measurement [36] .
Berger et al. [37] proposed using both subjective and actigraphy-measured sleep to evaluate various aspects of sleep in women with breast cancer to increase sensitivity and abate missing data. Thus, generally, clinicians and researchers who treat and study sleep disruption rely on both objective measures (actigraphy or PSG) and self-reports (sleep diaries, questionnaires) for assessment of sleep [12] . This suggestion was also endorsed by Dhruva et al. [15] , who advocated for a comprehensive and longitudinal evaluation of this symptom trajectory in order to more accurately identify potential targets for intervention.
While we did not find agreement between our subjective and objective sleep measurements, we observed that patients with poor subjective sleep also had a significantly more disrupted circadian rhythm, as measured by lower I \ O index (Fig. 2) . It is possible that the dichotomy index is a more sensitive marker of perceived sleep function because it takes both daytime and nighttime activity into account [21, 22, 26] . Indeed, patients who complained of poor sleep allegedly suffered from consequences of unrestful sleep during daytime, and the circadian rest-activity rhythm was reported as a correlate to fatigue [8, 25] , an expected repercussion of altered nighttime sleep [38] .
Interestingly, in our study, patients who reported subjective sleep complaints and had circadian disruption demonstrated significantly worse outcomes on pertinent health-related quality of life subscales than those with only one disruption or none, suggesting that there might be a Fig. 2 Distribution of the circadian parameter I \ O, according to the presence (grey boxes) or absence (white boxes) of subjective sleep complaints derived from the EORTC QLQ-C30. Boxplots represent 1st and 3rd quartiles, whiskers the range, and the middle black line the median. The p value is derived from nonparametric Mann-Whitney U test. The best cutoff value to discriminate between healthy subjects and cancer patients is 99%, [22] while the most clinically relevant cutoff value in advanced colorectal cancer patients, in term of prognosis, is 97.5% [8, 19] cumulative, negative impact on patients' well-being from experiencing poor subjective sleep and disrupted circadian function (Fig. 3) .
This study is relevant within the larger context of cancer patient well-being. Indeed, patient-reported outcomes are being increasingly recognized as valid and reliable measurements, with important clinical relevance [39, 40] . This recognition given to patient-reported outcomes seems particularly appropriate for sleep quality, a common, bothersome, yet overlooked problem in cancer patients [13] . Similarly, circadian function is rarely evaluated in cancer patients, despite its clinical impact [3, 8] . While our findings further support the concomitant evaluation of subjectively reported symptoms and of objectively measured circadian function in future studies in cancer patients, they also highlight the need for more sensitive, noninvasive measures of sleep and circadian disruption.
The cumulative and negative clinical impact of altered sleep and circadian functions further supports the development of research strategies for novel, targeted interventions to normalize circadian homeostasis. Given the reported prognostic impact of poor sleep [17, 32] and of circadian disruption [3, 18, 19] in cancer patients, improving circadian function with associated improvements in sleep might potentially improve overall survival.
We acknowledge the main limitation in our study, which is the lack of use of a benchmark sleep questionnaire in cancer patients [12] . Instead, we used a single-item question, although face-valid, to screen for sleep complaints, precluding us from evaluating self-reported sleep duration, sleep maintenance, or relevant sleep-related daytime dysfunction, which could have been examined in relation to actigraphic data. These additional data would have been informative given the absence of differences in objective sleep duration/sleep continuity measures between subgroups of patients with or without sleep complaints. Using a one-item sleep question, in comparison with a validated measure (e.g., Pittsburgh Sleep Quality Index or Insomnia Severity Index), provides less information and yields different sensitivity and specificity values compared to a more detailed evaluation of sleep.
Additional subjective sleep disruption questions might have helped elucidate our findings; however, a self-report measure of sleep disruption involving multiple questions may still not have more fully captured a patient's distinct forms of sleep disruption due to the possibility that these distinct forms are unrecognized by the patient. Furthermore, the aim of our study was to identify objective measures of subjective sleep complaints and not to evaluate the incidence of specific facets of sleep disruption. The single-item question used in the current study was included in a validated, broadly used questionnaire in cancer patients [28] , had demonstrated clinical relevance in patients with metastatic colorectal cancer [17] , and did not require the complicated retrospective recall of sleep experiences, unlike other multi-item sleep questionnaires. This one-item question was valid in discriminating patients with and without circadian disruption. In addition, using a one-item measure for sleep to screen patients with sleep problems in a busy oncology clinic might be more acceptable and feasible. Our findings provide evidence for a rather weak association between wrist-actigraphy conventional estimates of poor sleep and patients' own impressions of having trouble sleeping, but our findings are not suitable to precisely gauge the incidence and type of sleep pathologies or the entire range of their daytime consequences on the patients. Additional studies incorporating multidimensional evaluations of sleep, ideally on an individual night basis, are warranted to further address these issues.
Another limitation of this study is the use of wristactigraphy measurement for assessment of circadian disruption. Actigraphy only approximates circadian rhythms; to accurately measure circadian disruption would require patients to be observed in the laboratory under stable light, food, and activity conditions while undergoing continuous biomarker measurement, which is not realistic given the clinical sample. Nevertheless, this study has many strengths, such as a large sample size of patients with metastatic disease, an objective evaluation of sleep and circadian function for at least 72 h performed in a clinical setting, and the availability of a multidimensional array of patient-reported outcomes.
The goal of our study was to evaluate subjective and objective evidence of sleep and circadian disruption in patients with metastatic colorectal cancer and to examine the effect of sleep and circadian dysfunction on healthrelated quality of life. Interestingly, we found that subjective sleep difficulty correlated positively with objective circadian disruption (Fig. 2) . In our sample, we found no relationship between subjective sleep disruption and objective sleep disruption as measured by actigraphy (Fig. 1) . These novel findings add to the paucity of literature regarding sleep problems and circadian disruption in patients with metastatic colorectal cancer. Sleep problems are common but are undertreated and underrecognized in cancer patients, particularly in those diagnosed with metastatic disease. Evaluating and treating sleep and circadian problems can significantly improve quality of life in patients diagnosed with metastatic cancer. Future research should examine the impact of behavioral and/or pharmacological interventions with the aim to normalize both circadian and sleep disruption to understand whether such interventions could improve quality of life and potentially overall survival.
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